HIND
NASDAQ · Pharmaceuticals
Vyome Holdings Inc
$2.29
-0.03 (-1.29%)
Financial Highlights (FY 2026)
Revenue
11.03B
Net Income
-9,827,389,831
Gross Margin
63.2%
Profit Margin
-89.1%
Rev Growth
-16.2%
D/E Ratio
—
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 63.2% | 63.2% | 51.8% | 51.8% |
| Operating Margin | -91.2% | -82.1% | 18.6% | 21.0% |
| Profit Margin | -89.1% | -84.6% | 20.8% | 19.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 11.03B | 13.17B | 5.84M | 4.87M |
| Gross Profit | 6.97B | 8.32B | 3.02M | 2.52M |
| Operating Income | -10,060,422,328 | -10,803,460,321 | 1.09M | 1.02M |
| Net Income | -9,827,389,831 | -10,553,216,618 | 1.21M | 947.3K |
| Gross Margin | 63.2% | 63.2% | 51.8% | 51.8% |
| Operating Margin | -91.2% | -82.1% | 18.6% | 21.0% |
| Profit Margin | -89.1% | -84.6% | 20.8% | 19.4% |
| Rev Growth | -16.2% | -16.2% | -9.0% | -7.3% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 0 | 7.09M | 8.20M |
| Total Equity | — | — | 9.03M | 10.37M |
| D/E Ratio | — | — | 0.79 | 0.79 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -9,763,987,518 | -11,067,638,876 | 1.81M | 1.57M |
| Free Cash Flow | — | — | 575.3K | 579.0K |